Blogs
3 February 2025
Polo-like kinase inhibitors increase AAV production by halting cell cycle progression
Recombinant adeno-associated viruses (rAAVs) are commonly used in gene therapy for preclinical research and therapeutic applications. Despite the clinical...
Read More1 February 2025
Recombinant AAV batch profiling by nanopore sequencing
Recombinant AAV vectors are widely used for in vivo gene therapy in all stages ranging from pre-clinical to clinical...
Read More26 November 2024
The deep roots of gene therapy in Florida
Scientists have known about adeno-associated virus (AAV) for more than six decades. Researchers from around the world have been...
Read More3 September 2024
Gene therapy CDMOs play critical role in enabling AAV process improvement & standardization
Wes McConnell, CFO at Ascend The approval of numerous gene and gene-modified cell therapies by regulatory agencies around the...
Read More1 August 2024
Enhancing AAV production using high-throughput screens and rational design
Mo Mandegar, dPhil – Vice President and Head of Site, Alameda Adeno-associated viruses (AAVs) have emerged as a favored...
Read More17 June 2024
The Importance of AAV Process Comparability Throughout Development
Relying on unscalable cell-culture processes during early stages can be fatal for product development. Markus Hörer, Chief Scientific Officer...
Read More